TEVA PHARMACEUTICAL-SP ADR (TEVA) Fundamental Analysis & Valuation

NYSE:TEVA • US8816242098

Current stock price

34.95 USD
-0.12 (-0.34%)
At close:
34.95 USD
0 (0%)
After Hours:

This TEVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TEVA Profitability Analysis

1.1 Basic Checks

  • TEVA had positive earnings in the past year.
  • TEVA had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: TEVA reported negative net income in multiple years.
  • Each year in the past 5 years TEVA had a positive operating cash flow.
TEVA Yearly Net Income VS EBIT VS OCF VS FCFTEVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B -15B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.46%, TEVA belongs to the top of the industry, outperforming 83.25% of the companies in the same industry.
  • TEVA's Return On Equity of 17.81% is amongst the best of the industry. TEVA outperforms 89.53% of its industry peers.
  • The Return On Invested Capital of TEVA (12.03%) is better than 91.10% of its industry peers.
  • TEVA had an Average Return On Invested Capital over the past 3 years of 10.53%. This is below the industry average of 13.07%.
  • The 3 year average ROIC (10.53%) for TEVA is below the current ROIC(12.03%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROIC 12.03%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
TEVA Yearly ROA, ROE, ROICTEVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • With an excellent Profit Margin value of 8.16%, TEVA belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
  • TEVA has a Operating Margin of 24.09%. This is amongst the best in the industry. TEVA outperforms 91.62% of its industry peers.
  • TEVA's Operating Margin has improved in the last couple of years.
  • TEVA has a Gross Margin of 52.72%. This is in the better half of the industry: TEVA outperforms 63.87% of its industry peers.
  • In the last couple of years the Gross Margin of TEVA has grown nicely.
Industry RankSector Rank
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
TEVA Yearly Profit, Operating, Gross MarginsTEVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TEVA Health Analysis

2.1 Basic Checks

  • TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for TEVA has been increased compared to 1 year ago.
  • Compared to 5 years ago, TEVA has more shares outstanding
  • Compared to 1 year ago, TEVA has an improved debt to assets ratio.
TEVA Yearly Shares OutstandingTEVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
TEVA Yearly Total Debt VS Total AssetsTEVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • Based on the Altman-Z score of 1.05, we must say that TEVA is in the distress zone and has some risk of bankruptcy.
  • TEVA has a Altman-Z score of 1.05. This is comparable to the rest of the industry: TEVA outperforms 51.83% of its industry peers.
  • TEVA has a debt to FCF ratio of 14.64. This is a negative value and a sign of low solvency as TEVA would need 14.64 years to pay back of all of its debts.
  • TEVA has a Debt to FCF ratio of 14.64. This is in the better half of the industry: TEVA outperforms 76.96% of its industry peers.
  • A Debt/Equity ratio of 1.90 is on the high side and indicates that TEVA has dependencies on debt financing.
  • TEVA's Debt to Equity ratio of 1.90 is on the low side compared to the rest of the industry. TEVA is outperformed by 81.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Altman-Z 1.05
ROIC/WACC1.51
WACC7.98%
TEVA Yearly LT Debt VS Equity VS FCFTEVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • TEVA has a Current Ratio of 1.04. This is a normal value and indicates that TEVA is financially healthy and should not expect problems in meeting its short term obligations.
  • TEVA's Current ratio of 1.04 is on the low side compared to the rest of the industry. TEVA is outperformed by 84.82% of its industry peers.
  • A Quick Ratio of 0.80 indicates that TEVA may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.80, TEVA is doing worse than 84.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.8
TEVA Yearly Current Assets VS Current LiabilitesTEVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TEVA Growth Analysis

3.1 Past

  • TEVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.81%, which is quite good.
  • TEVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.89% yearly.
  • TEVA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
  • The Revenue has been growing slightly by 0.71% on average over the past years.
EPS 1Y (TTM)15.81%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%1.92%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%2.34%

3.2 Future

  • Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 6.21% on average per year.
  • Based on estimates for the next years, TEVA will show a small growth in Revenue. The Revenue will grow by 1.72% on average per year.
EPS Next Y-6.32%
EPS Next 2Y3.42%
EPS Next 3Y6.21%
EPS Next 5YN/A
Revenue Next Year-1.72%
Revenue Next 2Y0.59%
Revenue Next 3Y1.72%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TEVA Yearly Revenue VS EstimatesTEVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5B 10B 15B 20B
TEVA Yearly EPS VS EstimatesTEVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

7

4. TEVA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 11.85, the valuation of TEVA can be described as reasonable.
  • Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 89.01% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.77, TEVA is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.12 indicates a reasonable valuation of TEVA.
  • TEVA's Price/Forward Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 85.34% of the companies in the same industry.
  • TEVA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.75.
Industry RankSector Rank
PE 11.85
Fwd PE 11.12
TEVA Price Earnings VS Forward Price EarningsTEVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 86.39% of the companies listed in the same industry.
  • 81.68% of the companies in the same industry are more expensive than TEVA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 35.46
EV/EBITDA 10.48
TEVA Per share dataTEVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • TEVA has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.42%
EPS Next 3Y6.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TEVA Dividend Analysis

5.1 Amount

  • No dividends for TEVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEVA Fundamentals: All Metrics, Ratios and Statistics

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (5/1/2026, 4:15:00 PM)

After market: 34.95 0 (0%)

34.95

-0.12 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)04-29
Earnings (Next)05-12
Inst Owners21.22%
Inst Owner Change-0.15%
Ins Owners0.47%
Ins Owner Change13.72%
Market Cap40.70B
Revenue(TTM)17.26B
Net Income(TTM)1.41B
Analysts82.86
Price Target0.11 (-99.69%)
Short Float %2.61%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.53%
Min EPS beat(2)16.51%
Max EPS beat(2)38.54%
EPS beat(4)4
Avg EPS beat(4)16.39%
Min EPS beat(4)4.65%
Max EPS beat(4)38.54%
EPS beat(8)7
Avg EPS beat(8)8.31%
EPS beat(12)9
Avg EPS beat(12)5.55%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)2
Avg Revenue beat(2)3.32%
Min Revenue beat(2)0.9%
Max Revenue beat(2)5.75%
Revenue beat(4)2
Avg Revenue beat(4)-0.7%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)5.75%
Revenue beat(8)5
Avg Revenue beat(8)0.11%
Revenue beat(12)8
Avg Revenue beat(12)1.11%
Revenue beat(16)8
Avg Revenue beat(16)-0.59%
PT rev (1m)-0.09%
PT rev (3m)2.27%
EPS NQ rev (1m)5.46%
EPS NQ rev (3m)-4.1%
EPS NY rev (1m)-0.92%
EPS NY rev (3m)-2.64%
Revenue NQ rev (1m)3.4%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)-0.74%
Revenue NY rev (3m)-2.23%
Valuation
Industry RankSector Rank
PE 11.85
Fwd PE 11.12
P/S 2.36
P/FCF 35.46
P/OCF 24.68
P/B 5.15
P/tB N/A
EV/EBITDA 10.48
EPS(TTM)2.95
EY8.44%
EPS(NY)3.14
Fwd EY8.99%
FCF(TTM)0.99
FCFY2.82%
OCF(TTM)1.42
OCFY4.05%
SpS14.82
BVpS6.79
TBVpS-10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.2322 (-39.25%)
Profitability
Industry RankSector Rank
ROA 3.46%
ROE 17.81%
ROCE 15.24%
ROIC 12.03%
ROICexc 13.83%
ROICexgc 82.57%
OM 24.09%
PM (TTM) 8.16%
GM 52.72%
FCFM 6.65%
ROA(3y)-0.66%
ROA(5y)-1.34%
ROE(3y)-6.71%
ROE(5y)-9.48%
ROIC(3y)10.53%
ROIC(5y)9.34%
ROICexc(3y)11.98%
ROICexc(5y)10.44%
ROICexgc(3y)70.07%
ROICexgc(5y)58.35%
ROCE(3y)13.34%
ROCE(5y)11.83%
ROICexgc growth 3Y24.16%
ROICexgc growth 5Y15.53%
ROICexc growth 3Y17.63%
ROICexc growth 5Y14.52%
OM growth 3Y3.96%
OM growth 5Y4.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.99%
GM growth 5Y2.49%
F-Score8
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF 14.64
Debt/EBITDA 2.91
Cap/Depr 50%
Cap/Sales 2.9%
Interest Coverage 4.38
Cash Conversion 31.96%
Profit Quality 81.48%
Current Ratio 1.04
Quick Ratio 0.8
Altman-Z 1.05
F-Score8
WACC7.98%
ROIC/WACC1.51
Cap/Depr(3y)47.55%
Cap/Depr(5y)45.36%
Cap/Sales(3y)3.08%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.81%
EPS 3Y4.89%
EPS 5YN/A
EPS Q2Q%1.92%
EPS Next Y-6.32%
EPS Next 2Y3.42%
EPS Next 3Y6.21%
EPS Next 5YN/A
Revenue 1Y (TTM)4.32%
Revenue growth 3Y4.96%
Revenue growth 5Y0.71%
Sales Q2Q%2.34%
Revenue Next Year-1.72%
Revenue Next 2Y0.59%
Revenue Next 3Y1.72%
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3Y9.12%
EBIT growth 5Y5.49%
EBIT Next Year16.89%
EBIT Next 3Y10.65%
EBIT Next 5YN/A
FCF growth 1Y53.27%
FCF growth 3Y3.28%
FCF growth 5Y12.47%
OCF growth 1Y32.24%
OCF growth 3Y1.22%
OCF growth 5Y6.28%

TEVA PHARMACEUTICAL-SP ADR / TEVA Fundamental Analysis FAQ

What is the fundamental rating for TEVA stock?

ChartMill assigns a fundamental rating of 5 / 10 to TEVA.


What is the valuation status of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

ChartMill assigns a valuation rating of 7 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.


What is the profitability of TEVA stock?

TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for TEVA stock?

The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 11.85 and the Price/Book (PB) ratio is 5.15.


What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?

The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.